It’s no secret that biotech is feeling it once again. Stocks are way up, and startups are seizing the opportunity to sail through a wide-open IPO window. That bull market isn’t just generating big returns for investors, it’s helping fuel the next round of innovation. Ambitious startups are sprouting up, sparked by science that is turning heads. New, nontraditional sources of cash are turning their attention to life sciences, creating unlikely options for fledgling biotechs that simply weren’t imagined a short time ago. But which ideas are generating the most buzz? What’s it going to take for the grandiose visions to become reality? And what does it all mean for drug discovery and health? Join Xconomy as we bring together some of the Boston biotech scene’s top innovators, venture capitalists, and executives, who are at the forefront of some of the biggest new ideas in life sciences.

Confirmed speakers:
Michael Bonney, CEO, Cubist Pharmaceuticals
Douglas Williams, EVP, Research and Development, Biogen Idec
John Maraganore, CEO, Alnylam Pharmaceuticals
Rob Armstrong, former VP, Global External Research and Development, Eli Lilly
David Berry, CEO, Seres Health; Partner, Flagship Ventures
Kevin Bitterman, Interim CEO, Editas Medicine; Partner, Polaris Partners
Katrine Bosley, Entrepreneur-in-residence, The Broad Institute
Steven Holtzman, EVP, Corporate Development, Biogen Idec
Andrew Lo, Professor of Finance, MIT Sloan School of Management
Jason Rhodes, President and CFO, Epizyme
Nancy Simonian, CEO, Syros Pharmaceuticals
Robert Urban, Head, J&J Innovation Center, Boston
Feng Zhang, Professor of Biomedical Engineering, MIT

Schedule:
Registration: 12:30 – 1:30 pm
Program:  1:30 – 5:30 pm
Networking Reception: 5:30 – 6:30 pm
View full agenda

Twitter:
@Xconomy
#xconBio

Registration information:
Tickets are transferable but not refundable.
To inquire about press registration, e-mail events@xconomy.com.